The benefits of dual (DDD) over single chamber pacing (WI) have been demonstrated in haemodynamics, exercise capacity, quality of life and reduced complications in atrioventricular block and sick sinus syndrome.
Introduction
In the major indications for permanent cardiac pacing, which are sick sinus syndrome and atrioventricular block' 1^*1 , many studies have shown a benefit of dualover single-chamber WI pacing. The benefit is in terms of better haemodynamics, exercise capacity, quality of life and reduced complications. Sufficient data are now available to permit an analysis of cost benefit based on the published rates of complications in the two modes of pacing 151 , but this does not include the cost benefit of quality of life improvements. In the foreseeable future, Number of patients Monthly incidence (SD) Yearly incidence (SD) 11 (10) *The number of patients with pre-existing AF have been deleted from the calculation.
•*T value 65-63 /><0-0009. ***T value 52-08 /><00009. in many instances. Rate modulated modes of pacing Likewise the survival, the incidence of heart failure and (VVIR and DDDR) were excluded from the analysis at atrial fibrillation, the occurrence of stroke and its this stage and device malfunctions have also not been complicating permanent disability were taken from included. reports [l-6~32 ' of the long-term follow-up of patients The complications taken into account were atrial with sick sinus syndrome and atrioventricular block, fibrillation, stroke, disability as a result of stroke, heart Table 1 summarises the data in sick sinus syndrome failure, pacemaker syndrome and mortality. Others patients on the monthly incidence of atrial fibrillation, could readily be added but these were considered to atrioventricular block and mortality. The incidence of be the most important. In WI pacing, upgrading to stroke was calculated as 30% of the incidence of atrial dual chamber pacing was included when necessary, fibrillation and a similar percentage for disability in Pacemaker-mediated tachycardia was deliberately omit-relation to stroke. Disability and heart failure were ted as it does not contribute significantly to morbidity or considered permanent. Upgrading to dual chamber cost. For the purposes of this calculation the incidence pacing was assumed to be undertaken in 5% per of syncope was considered to be zero, as in the two annum in sick sinus syndrome and atriovenindications assessed its incidence largely relates to device tricular block patients paced WI. This is constituted failure. Supplementary calculations were permitted for as half the incidence of heart failure plus the total assessment of AAI pacing in sick sinus syndrome includ-incidence of pacemaker syndrome. This figure is ing the incidence of atrioventricular block requiring conservative as it is less than the 8% figure per annum upgrading to dual chamber pacing.
found in a 5 year review of patients paced at In this analysis data from the literature on Westminster Hospital (1985) (1986) (1987) (1988) (1989) (1990) where an overall DDD and AAI pacing in sick sinus syndrome were rate of over 80% of dual chamber pacing was practised considered to be equivalent and therefore combined, (unpublished data).
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Cost calculations
An arbitrary currency unit was chosen in order to permit international comprehension of the cost aspect which was based on the cost of a VVI generator being 100 units of currency, based on U.K.. prices: the device costs were derived from a survey of six manufacturers active on the U.K.. market.
The cost of procedures, hospitalization and medication was calculated on the basis of U.K.. prices in 199! [5] (x a ble 2), since when inflation has been <3% per annum. For future years constant costs were assumed. The implantation costs were assessed from Westminster Hospital costs compiled for use in the British National Health Service contracting system. For single chamber systems 45 min in the operating room was taken and 60 min for dual chamber pacemakers; all patients were calculated to spend 2 hospital nights as an inpatient. Follow-up costs were taken similarly from Westminster Hospital contract negotiation calculations. The cost of atrial fibrillation therapy and outpatient management was derived as above. Stroke was assumed to require 7 inpatient days for evaluation and treatment and the cost of permanent disability was again based on local figures for long-term care. Heart failure was treated with angiotensin converting enzyme inhibitors and frusemide at standard U.K. prices in average doses. One week of inpatient therapy per year for heart failure was included in the cost of this complication. Upgrading costs included a new generator and an additional pacing lead as well as 60 min of operating room usage, one night's hospital stay and the waste of resources involved in disposing of the redundant generator. Patients who died were considered not to contribute further to the costs.
Computer model
A computer model was developed to calculate over a 10 year period the incidence and prevalence of atrial fibrillation, stroke and permanent disability, heart failure and mortality using a Lotus 123r4 programme (version 4.01) on a Toshiba T 3400CT subnotebook, which has a 486 SX microprocessor with a 20 Megabyte RAM. For each year, the number of surviving patients, the number of patients with chronic atrial fibrillation, the number of strokes, the number of patients with disability due to a cerebrovascular accident and the number of patients with heart failure were calculated for the following categories: patients with sick sinus syndrome with a VVI pacemaker; patients with sick sinus syndrome upgraded to a DDD pacemaker; patients with sick sinus syndrome with a DDD pacemaker as the initial implant; patients with atrioventricular block with a VVI pacemaker; patients with atrioventricular block upgraded to a DDD pacemaker; patients with atrioventricular block with an initial DDD pacemaker.
The model allows for the possibility that the first year incidence of all variables may be different from those in the second and subsequent years. The model has the flexibility to allow independent variations in 156 parameters, the exception being that mortality of patients is identical whether heart failure complicates the course or not; the figure used was an average. Increased mortality from atrial fibrillation has also not been taken into consideration, since no data are available in the cardiac pacing literature. As the calculation was based on an intention to treat basis, the cost of the upgraded patients was added to the cost of the patients with WI units.
A sensitivity analysis of the most important parameters was carried out to evaluate the impact of the assumption on the total cost. In the atrial fibrillation and mortality analysis, the upgraded patients had the same atrial fibrillation and mortality incidence as the patients with VVI pacemakers.
The impact of the assumption that 30% of the atrial fibrillation patients will have a stroke, was analysed by varying this ratio between 5 and 40%. Also the yearly incidence of heart failure was evaluated from an incidence of 1% to 19% and of mortality from 2 to 10%. Similarly, the influence of the annual cost of disability and heart failure treatment on the total cost were evaluated by varying these costs over a wide range (750-2750 units for disability and 50-400 units for heart failure). 29 -321 including 4111 patients where the yearly incidence varied from 0-14%. The average yearly incidence is 8-3% (± 38 SD) for VVI patients and 1-7±1-4SD for atrially paced patients. For calculation purposes, the incidence of atrial fibrillation (Table 3) was taken for the first and following years, respectively, as 10% and 7% in WI pacing for sick sinus syndrome and 2% and 1-5% in DDD mode. In atrioventricular block the incidence of atrial fibrillation was calculated from four reports'" • Cost benefit analysis in pacing 577 0-5% 015% 0045% 2% 0% 5% SSS = sick sinus syndrome, AVB = atrioventncular block yearly mean stroke incidence of 32% for VVI and 0-6% for atrially paced patients could be calculated. This indicates a ratio stroke/atrial fibrillation incidence of 39%. The incidence of heart failure in sick sinus syndrome patients was 6-5% for WI patients and 21% for atrially paced patients. These numbers are based on 414 patients in four reports' 1 ' 67 ' 91 . The results of the cost benefit analysis covering a 10-year period are shown in Tables 4-7 . There is an important difference in survival with extensive use of DDD pacemakers (Table 4 ). Approximately 24 of 57 Table 5 Patients with heart failure or severe disability as % of survivors survivors of a sick sinus syndrome-WI strategy would have been upgraded to a DDD pacemaker and for an atrioventricular block-VVI strategy, 21 of 51 survivors would have been upgraded. At 10 years there are also important differences in the number of patients in heart failure ( Table 5) . A DDD strategy reduces its incidence to less than half. The most striking difference between the two strategies is the effect of DDD pacing in decreasing atrial fibrillation (Table 5 ). This resulted in a lower stroke incidence which led to a five-fold reduction of severe disability.
Results
The calculation shows that the cost of WI approximates that of DDD pacing in both indications early in the 3rd year after implantation ( Table 6 ), but that from the 3rd year on the cost of WI clearly exceeds that of DDD. The 10 year cumulative cost per initial implantation is 12 times the initial cost for sick sinus syndrome patients and close to 8 times for atrioventricular block patients. The cost of a replacement DDD unit has not been included, but on the basis of a 6-year lifetime, 249 units can be added to the DDD cost. However, for the VVI patients this figure requires adaptation due to the replacement of expired DDD units in the upgraded patients. For sick sinus syndrome and atrioventricular block patients these figures are 29 and 26 units, respectively, resulting in a cost differential, respectively, of 230 units and 233 units. The power and flexibility of the model is illustrated in Figs 1-4 , which show the sensitivity analysis. In Fig. 1 , cost is plotted against the incidence of atrial fibrillation where that in upgraded patients was consid- Figure 4 Shows the 10-year cumulative cost as a function of the incidence of heart failure. To estimate the cumulative cost differential one should take the cost at the appropriate heart failure incidence 6% in VVI patients and 2% for DDD patients. See Fig. 1 for explanation of symbols.
ered to be the same as in VVI units. With an increasing incidence of atrial fibrillation, the cost increases. The favourable cost differential of DDD vs VVI in sick sinus syndrome patients with an incidence of atrial fibrillation of 1% of 530 units, reverses to an unfavourable cost of 1385 units at an atrial fibrillation incidence of 19%. In atrioventricular block, DDD, with an incidence of atrial fibrillation of 1%, has a cost advantage of 323 units which vanishes at an incidence of atrial fibrillation slightly below 7%; this is well above the observed mean incidence of 0-7%. To estimate the cost differential one should bear in mind that clinical practice indicates that the relative incidence of atrial fibrillation is five times lower with DDD than with WI pacing (Table 1) . Figure 2 shows the costs as a function of the ratio of the incidence of stroke/atrial fibrillation as it varies from 5 to 40%. With the higher ratio the cost increases. The cost difference of a DDD strategy expressed as a percentage of the WI cost varies as the ratio of stroke/atrial fibrillation increases, and is, in sick sinus syndrome, at a 10% ratio 49% (810 units) increasing to 54% (1335 units) at a 30% ratio. In atrioventricular block patients, the differences are 40% (468 units) and 52% (859 units), at the same ratios.
The total cost varies with the yearly disability cost (Fig. 3) . The relative cost increase of a WI strategy is 54% for sick sinus syndrome and 52% for atrioventricular block at a disability cost of 1750 units. These percentages vary, with disability costs from 750 to 2750 units from 50% to 57% for sick sinus syndrome and 42% to 58% for atrioventricular block.
If the incidence of heart failure increases, the cost also rises (Fig. 4) , but the cost difference between a single vs a dual chamber strategy is reduced in sick sinus syndrome; in atrioventricular block, however, the differences greatly increase. The relative cost difference between a DDD and a WI patient is 54% for sick sinus syndrome and 52% for atrioventricular block and varies by <2% over a range of costs for heart failure treatment, from 50-400 units. Clinical experience indicates a lower incidence of development of heart failure in dual chamber pacing systems'
With increasing mortality from 2 to 10% there is an overall cost reduction which is more pronounced with WI pacing than with DDD. In sick sinus syndrome costs for WI and DDD become equal if there is an annual mortality of 17%; for atrioventricular block, costs become equal for single-and dual-chamber systems when the annual mortality is 22%. However, such high mortality figures have never been reported 133 "
381
. If it is assumed that there is an annual disability cost per patient of 1733 units, the disability costs in sick sinus syndrome patients are 55% as compared to 38% of the cumulative cost at 10 years if patients have WI as compared to DDD devices. In patients with atrioventricular block those costs represent 41% for WI vs 16% for DDD devices of the total cumulative cost (see Table  7 ). The cost of treatment of heart failure is 28% for WI vs 21% for DDD in sick sinus syndrome patients and 31% and 22%, respectively, in patients with atrioventricular block (see Table 7 ).
Discussion
All health care economies now demand the lowest costs for the highest patient benefit. The current approach of some physicians has been to maximize clinical benefit, thereby incurring increased initial costs if more complex cardiac pacing systems are used. There is a need to analyse the major outcomes of pacemaker patient care: an approach not previously addressed in this field. However, similar analyses have been performed in cardiology to assess, for example, the benefits of coronary angioplasty vs coronary bypass surgery 1391 or angioplasty vs thrombolysis' 401 . A study such as this inevitably implies limitations: for example, we have not included rate-responsive pacing systems as the available data are relatively limited and there is a probability that there are differences compared with pacing at a single rate. The data for AAI, DDD, DDI and DVI in sick sinus syndrome have been pooled because it was felt that all these modes offer atrial stimulation as opposed to ventricular stimulation alone (WI). It is important to emphasize that in the available studies for review there was no matching of patients, with the exception of Anderson et alP 2] . Our calculations have assumed that all complications have occurred linearly from the commencement of the studies analysed. This must be considered a limitation as this is clearly not always the case; for example, in the series published, the majority of the incidence of atrial fibrillation occurs in the first year 11 ' 1012141 . Also, if a linear calculation is done over several years it provides a relative underestimation of the incidence of 10% over a period of 5 years.
It is important to state that device failures have not been included in the analysis and that this is also a limitation of the study. However, the model lends itself to their inclusion. Moreover, assuming a 5% lead dislodgement rate in dual-chamber pacing modes and 2% in WI mode The definition of chronic atrial fibrillation is always difficult as authors' estimates of this condition vary. We have taken the authors' assessment in each case.
When DDD patients develop atrial fibrillation and are changed to W1
[3I) , complications may be high, but there is insufficient literature on this type of patient to permit any calculation.
In this analysis, only papers published in the last 10 years were examined so as to keep the data as contemporary as possible. Care was taken to include only the latest published data from each centre. Unfortunately some papers were excluded as it was impossible to assess the data sufficiently well for the analysis' We have recognised that it is often difficult to compare one author with another because of different patient selection and this may explain the mortality differences between centres. Also, there could be a selection bias in a centre in the use of dual-chamber devices relative to WI units based on cost, patient life expectancy and lifestyle.
Peripheral embolism is not included in the model used here and thus the costs which reflect stroke due to systemic embolism are understated 17 ' 20 -341 ; these may be as frequent as stroke in terms of incidence and incur some cost. Secondly, some incidence of stroke may not have been embolic but thrombotic or haemorrhagic, but since pacing only benefits embolic stroke, this may have resulted in an over-estimation of costs 110 '. The incidence of stroke in patients with atrial fibrillation reported in the anticoagulation literature is between 2 and 8%, which is quite low relative to the reports on pacemaker patients. Andersen et alP 2] reported an incidence of 23% and 17-4% for atrial fibrillation and thromboembolic incidence, respectively, in the VVI group vs 14% and 5-6% for the AAI group. Other authors' 7 ' 101 reported that half of the thromboembolic events result in stroke, while our calculation shows a ratio of stroke to atrial fibrillation incidence of 39%. It has been suggested that 30% is the rate at which disability complicates stroke; this is considered to be a relatively conservative figure. Sgarbossa etal) w] found that roughly 31% of strokes are minor, 50% are disabling and 19% are fatal. Andersen et alP 2] reported seven deaths in the VVI group of which six were from stroke and two in the AAI group of which one was from stroke. Santini et a/.
1 ' 61 reported a higher stroke incidence in the elderly.
Mortality has not been quoted separately for its associations, for example, with acquired heart failure. Alpert et a/.
1361 and Linde-Edelstam et a/. [37] in a small series indicate the survival in patients with pre-existing heart failure is higher for dual chamber pacing than for VVI. Zanini et a/.
138
' indicate a similar survival for atrioventricular block and sick sinus syndrome during the first 10 years and later a better survival for sick sinus syndrome. A recent paper by Tung et alP 3] indicates that sick sinus syndrome patients survive better with DDD pacemakers relative to WI devices. It was not significant, but it is worthy of note that the group of patients receiving dual chamber devices included close to five times more patients with pre-implant cardiomyopathy than the VVI group. Shen et a/. [35] also recently reported survival in patients with atrioventricular block over 65 years of age, indicating significant differences with age and pre-existing heart failure, but the authors do not report differences in pacing mode. The model can be adapted for the difference in mortality with pre-existing heart failure, acquired heart failure, and without heart failure. Hitherto, only a few papers have been published with this level of precision of data.
Use of the international currency unit reveals that the ratio of cost of DDD vs WI pacing is similar from one country to another. For the cost benefit analysis we have chosen to analyse only a few complications of the common conditions and their treatment, but the computer model is capable of analysing many more. However, in most cases the data on which to base calculations are lacking.
By this novel approach, we have not only shown what we believe is the true cost implications of a 'VVI for all' implantation policy, but have also provided a means to calculate the minimum number of patients to be included in future studies to obtain clinically meaningful results. Furthermore, we have illustrated considerable areas where data are lacking in the field of cardiac pacing. Future prospective trials are needed to amplify the possible benefits. Previous pacing literature has taken little or no account of the effect of permanent disability on the cost outcome of the therapy. Perhaps this is because the patients are taken care of by other physicians, but this study shows that permanent disability is such a major complication in terms of its cost implications that it should be included in all future pacing studies of clinical performance.
Savings achieved by implanting AAI units instead of dual chamber units in sick sinus syndrome patients are offset by the need to upgrade in cases of atrioventricular block, which has a yearly incidence of 11%± 10SD (Table 1) . Also, those patients with AAI units are at risk of syncope, which bears a relatively high cost in terms of bony fractures, ambulance journeys and emergency room assessments 151 . Depending on the incidence of syncope the cost impact could vary from 7% decrease to a 4% increase.
Conclusion
The conclusion to be drawn from this study is that a physiological approach to pacing, taking account of immediate and long-term effects, is both clinically and cost effective.
Unlike therapy with pharmaceutical agents, cardiac pacing requires an initial investment which is greater for dual-than for single-chamber systems, but the reduced complication rate of the dual-chamber choice pays off 3 years after the implant.
